Navigation Links
Affymetrix and bioMerieux Extend Their Agreement on GeneChip(R) Technology to Breast Cancer Diagnostics

Affymetrix Inc. (Nasdaq: AFFX) and bioMerieux announced today that Affymetrix has granted bioMerieux long-term and comprehensive access to its GeneChip(R) technology to develop and market in vitro diagnostic tests for breast cancer, as well as an option to expand the agreement into other cancer areas.

The agreement, made under the Powered by Affymetrix(TM) program, gives bioMerieux non-exclusive rights to Affymetrix' patented arrays, instrumentation systems and future improvements to these key technologies. Financial terms of the agreement were not disclosed.

"Microarrays are on the path to becoming a clinical reality in oncology, helping clinicians to provide a more holistic understanding of disease and treatment," said Dr. Dirk Lammerts, M.D., Affymetrix' Vice President of Molecular Diagnostics. "bioMerieux is at the cutting edge of diagnostic technology and we are pleased that they have chosen the Affymetrix platform for this project."

Under the Powered by Affymetrix(TM) program, Affymetrix provides technology and expertise for products that are developed, branded and marketed by diagnostic companies. This includes the GeneChip System 3000Dx, which has been granted regulatory clearance by the U.S. Food and Drug Administration and CE marked in the European Union for in-vitro diagnostic use.

"bioMerieux provides a full range of solutions for molecular diagnostics, from single to multiple and complex genetic targets, requiring the use of microarrays. Our extended agreement with Affymetrix broadens our rights beyond infectious diseases, food and water testing. The potential for microarrays in cancer application will be vast, ranging from diagnosis to personalized treatment," explained Dr Christophe Merieux, Vice President Research and Development - Medical Affairs.


'"/>

Source:Affymetrix


Page: 1

Related biology news :

1. Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
2. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
3. Affymetrix and the Karolinska Institutet Announce Translational Medicine Strategic Alliance
4. Affymetrix and Stratagene Announce Strategic Software Alliance
5. Affymetrix Licenses Microfluidics Technology From Caliper Life Sciences
6. Affymetrix Launches New Globin-Reduction Kits and Protocol Developed with PreAnalytiX
7. Affymetrix and ParAllele Launch Industrys Most Comprehensive Product Line for Targeted Genotyping
8. Genomatix Microarray Analysis Pipeline achieves Affymetrix GeneChip compatible?status
9. Affymetrix 500K array used to identify memory gene
10. HIV Therapy Greatly Extends Life of Key T Cells, Scientists Find
11. Scientists Propose Sweeping Changes to Naming of Bird Neurosystems to Acknowledge Their True Brainpower

Post Your Comments:
(Date:11/4/2009)... 2009 Childhood obesity in the United States is r...ourth of advertising on daytime and prime time tel...ing questions about the role television plays in o...the Journal of Nutrition Education and Behavior ...ght be a large contributor to the problem. , Res...
(Date:11/4/2009)...hat deciphered the DNA codes, or genomes, of the f...joined The Genome 10K Project, an international ef...ences on 10,000 species of animals for conducting ...not be achieved. , Participating in The Genome 1...Nov. 5, 2009 issue of the Journal of Heredity , a...
(Date:11/4/2009)..., Oct. 19 Spectros, developer and ...ging devices which shed light on life-threatening ...sive distribution deals for both its T-Stat® ...red include Australia, New Zealand, The Netherlan..., France, Spain, Portugal, Poland, Greece, Turkey,...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Singapore scientists join international study of 10,000 vertebrates' genomes 2Spectros Signs New International Distribution Deals 2Donor Sperm Providers Form New Non Profit 59569 1Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 59566 1Oaks Development Group Launches Physician Incubator Space in Palm Coast Medical Office Building 59566 2MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 1MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 2MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology 14494 3
...reasing amounts of ice mass have been lost from We... past ten years, according to research from the Un... in Nature Geoscience. , Meanwhile the ice mass ...either loss nor accumulation over the past decade.... Bristol and colleagues estimated the flux of ice ...
...N ARBOR, Mich.---Common genetic variants linked to... new study shows. , The international study was c...ic Health. The journal Nature Genetics will publis...onfirms observations by health professionals of a ...risk of osteoarthritis, the most common form of ar...
...tudies involving more than 35,000 people and a sur...al team supported in part by the National Institut...genetic variants recently linked to osteoarthritis...indings were released today in the advance online ...e variants most strongly associated with height in...
Other Biology News:Antarctic ice loss 2Study suggests genetic connection between short stature and arthritis 2Researchers uncover new piece to the puzzle of human height 2Researchers uncover new piece to the puzzle of human height 3Researchers uncover new piece to the puzzle of human height 4
(Date:11/6/2009)...r 6 EUCODIS Bioscience, a company,...ing enzymes for the,chemical industry announced to...with Bio Sidus, the leading biopharmaceutical comp...es EUCODIS Bioscience exclusive access - for the s...ietary collection of,psychrophilic bacteria strain...
(Date:11/6/2009)...da for Arrowhead’s 2010 Personalized Medicin...ace on February 22-24, 2010 in Philadelphia, has b...l highlight key issues in forming partnerships and...es. , Minneapolis, MN (PR...rsquo;s 2010 Personalized Medicine Partnerships C...
(Date:11/5/2009)...e-FirstCall/ -- Imagenetix, Inc. (OTC Bulletin Boa...resident and CEO of Imagenetix, will be presenting...nference on Thursday, December 3rd, at 10:30 AM PS...D MICRO ,, LD MICRO is a by-invitation only new...ompanies in the micro-cap space. Since 2002, the f...
(Date:11/5/2009)...RNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) t...g at the following investor conferences, and invit... Credit Suisse Healthcare Conference, Ph...2009 at 10 a.m. Mountain Time, NA... Tuesday, 1 December, 2009 at 10.45 ...
Breaking Biology Technology:EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3Imagenetix to Present at 2nd Annual LD MICRO Conference at the Luxe Sunset Bel Air 2Cepheid to Webcast Upcoming Financial Presentations 2
...2 Nektar,Therapeutics (Nasdaq: NKTR ) announced ...nsition from a drug delivery service provider to a...estructuring will,streamline the company, consolid...aking and execution within the business units., "... development company,and these changes are a natur...
...formance in 2007 and Notes Achievements over 4-ye... BioSciences, Preparing for Cha...ing-Plough,Corporation (NYSE: SGP ) today reporte...d full year, and commented on its ongoing integrat...cquired in November 2007 and,includes the Organon ...
...nternational,Corporation (Nasdaq: PRXL ) announce... 2-for-1 split of its Common Stock, which will be ...ers of PAREXEL,s Common Stock will receive one add...mmon Stock held on the record date of,February 22,...n or about,March 3, 2008 by PAREXEL,s transfer age...
Other Biology Technology:Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 2Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 3Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 2Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 3Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 4Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 5Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 6Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 7Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 8Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 9Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 10Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 11Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 12Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 13Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 14Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 15Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 16Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 17Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 18Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 19Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 20Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 21Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 22Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 23Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 24Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 25Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 26Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 27Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year 28PAREXEL International Announces 2-For-1 Stock Split 2PAREXEL International Announces 2-For-1 Stock Split 3
...tion. Cleaves a-(1-3)- and a(1-6)-linked, non-r...tes and glycoproteins. It is particularly efficien... where the pH must be neutral or above, for exampl...will hydrolyze 1 mole of p-nitrophenyl a-D-galacto...
ABI3100 Adapter for ABgene from ABgene
...2-Naphthoyl-VF-CHO White lyophilized solid. PROT...ermeable, reversible inhibitor of γ-secretas...40 (ED 50 = 2.6 μM) and Aβ x-42 (ED 50 ...ith the Amyloid Precursor Protein Swedish mutants....
Acl I (Psp1406 I) from New England Biolabs
Biology Products: